JITTERBIT
9.11.2021 09:02:10 CET | Business Wire | Press release
Jitterbit, the API transformation company, has revealed its first ever Integration Trends Report. It gives an unparalleled view of how companies responded to the seismic challenges of the global pandemic - and how they are building back stronger.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005727/en/
Analysing anonymised data of over 2,000 customers across EMEA from 2020 - 2021, the report reveals macro trends across markets as companies innovated to meet rapidly changing customer needs, move more of their services online and enable remote working for employees.
“The trends emerging all point to a need to move quickly and provide the highest level of product, service and employee experience in order to compete and survive, with companies turning to no-code/ low-code and microservices in readiness for the next stage of hypergrowth. ” said Steve Sichtman, VP Multi Channel Development, Jitterbit
Rather than freeze or reduce spend on integrating new technologies, companies actively sought to spend more on integration across a number of key areas:
Service Experience and eCommerce Spend
- With many physical locations closed or severely disrupted in 2020 and unprecedented customer demand for online service, companies responded by increasing their eCommerce integration investment by 99% during the year.
- Companies increased spend on Services Experience 360 on average by 50% in 2020. Growth in the services front-end with applications such as BMC Helix ITSM, Jira, Zendesk and others was also matched with growth in the services back-end around IT operations.
Product Experience
- Companies increased their spend on Product 360 (optimizing the product life cycle) in 2020 by 26%.
- Data from 2020 reveals a double digit increase in demand around large ERP systems from vendors like SAP and Microsoft. Optimizing business processes was a key focus as businesses realized the essential value of having automated processes across the entire manufacturing, supply chain and sales processes.
Employee Experience
- Companies increased their spend on Employee Experience 360 in 2020 by 72%. Increased reliance on a remote workforce, new communications tools, and fluctuating budgets all contributed to this increased focus on employee experience.
Low-code, microservice and marketplace popularity
- Low-code and no-code gained popularity because of the many hyper automation benefits it offers to IT teams, becoming in the process a key differentiator when selecting an integration platform-as-a-service (iPaaS).
- Many companies have already moved to microservices, rather than API, architecture. Self-contained and ready to go, microservices can be plugged into a wide array of applications and leveraged throughout an organization. Now, there’s evidence of increased demand for iPaaS systems that work closely with microservices. This empowers business users to plug different microservices together to create specialized applications without no-code.
- Many Enterprise and Software companies are finding it’s no longer sufficient to offer an API for the outside world to connect to them. They must overcome the “integration burden” to improve retention and stickiness. The answer lies in integration marketplaces where companies can offer pre-built and certified API integrations and solutions to their partners and customers.
This Integration Trends report demonstrates how trends in integration technology - the way modern businesses automate the connections between the myriad softwares, platforms and technologies they deploy - reflect how businesses respond to meet the macro challenges and opportunities they face.
The report also provides actionable insights on what businesses now need to focus on as countries across EMEA move into the post-pandemic period.
To download the full report, visit: https://info.jitterbit.com/jitterbit-trends-report.html
Ends.
About Jitterbit, Inc.
Jitterbit, the API transformation company, makes it quicker and easier for businesses to exploit data from any source, empowering them to rapidly innovate and make faster, more effective decisions. The Jitterbit Harmony API integration platform and API360 solutions enable companies to quickly connect SaaS, on-premises, and cloud applications and instantly infuse intelligence into any business process. To learn more, visit www.jitterbit.com or follow us on LinkedIn and on Twitter at @Jitterbit .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005727/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom